Asuragen is a molecular diagnostic company changing the way patients are treated in genetics and oncology. The quality, sensitivity and simplicity of our products are key to delivering true precision medicine. The company’s diagnostic systems, composed of proprietary chemistries and software, deliver powerful answers using widely available platforms. Asuragen’s approach starts by identifying a clinical need, where the lives of millions of patients can be impacted with the availability of complex molecular tests for diseases that are difficult to diagnosis and/or monitor. Asuragen is a product foundry rapidly addressing these significant current and emerging clinical needs with best-in-class diagnostic kits.
Location: United States, Texas, Austin
Employees: 201-500
Phone: +1 512-681-5200
Founded date: 2006
Investors 1
| Date | Name | Website |
| - | Telegraph ... | thpartners... |
Mentions in press and media 11
| Date | Title | Description |
| 04.01.2022 | Asuragen to Host “Advances in Practical, Broad Coverage CFTR Testing with the AmplideX® PCR/CE CFTR Kit*,” January 20, 2022 | Asuragen to Host “Advances in Practical, Broad Coverage CFTR Testing with the AmplideX® PCR/CE CFTR Kit*,” January 20, 2022 AUSTIN, Texas (PRWEB) January 04, 2022 Asuragen to hold “Advances in Practical, Broad Coverage CFTR Testing with the... |
| 07.07.2020 | Asuragen Announces CE Mark of AmplideX® SMA Plus Kit | The assay is intended to aid in the diagnosis of and identification of carriers for spinal muscular atrophy (SMA) AUSTIN, Texas–(BUSINESS WIRE)– Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex te... |
| 05.09.2018 | Asuragen Expands Oncology Portfolio with CE Marking and Launch of QuantideX® NGS DNA Hotspot 21 Kit | The panel accurately and sensitively detects over 1600 variants of clinical significance AUSTIN, Texas — Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy to use products for complex testing in genetics and onco... |
| 17.01.2018 | Asuragen Obtains CE Mark of QuantideX® qPCR BCR-ABL Kits on Roche Diagnostics cobas z 480 Analyzer | AUSTIN, Texas– Asuragen, Inc., a global molecular diagnostics product company changing the way patients are treated in genetics and oncology by bringing complex molecular tests to hospital and reference labs, today announced that it has exp... |
| 10.12.2014 | Three new biomarker companies selected to work with Abcodia and the Early Cancer Consortium | Three new biomarker companies selected to work with Abcodia and the Early Cancer Consortium 10-12-2014 Three new biomarker companies have been selected to work with the Early Diagnosis Consortium, a collaboration between Cancer Research UK,... |
| 24.10.2012 | MicroRNA-based cancer therapy firm scoops up $34.5 million, eyes 2013 IND filing | Solution/product: Mirna develops cancer therapies based on tumor suppressor microRNAs, which regain control over oncogenic pathways to kill cancer cells. MicroRNAs function as master regulators of the human genome and guide embryonic develo... |
| 08.08.2012 | Cancer diagnostics company using genomics analysis raising $1.3 million | Location: Pittsburgh, Pennsylvania. Solution/product: The biotechnology company uses genomics analysis to detect cancer. PathFinder TG uses molecular analysis of mutations in genomic DNA to provide a more accurate reading in cases where tra... |
| 03.04.2008 | Life-science briefing: Thursday, April 3, 2008 | TODAY’S HEADLINES: Mirna Thera spins out of Asuragen with $3M (release) Stroke-therapy startup CoAxia raises $12M (release) Stealthy device maker Synvascular gets $6.5M (peHUB) AndroScience seeks $3.5M for anti-testosterone drugs (VentureWi... |
| 10.12.2007 | Life sciences briefing: Monday, Dec. 10, 2007 | TODAY’S HEADLINES: Fundamental Applied Biology pulls in $21M for proteins without cells (release) Diagnostics maker Asuragen receives $19M (release) Stroke-device maker Neurovasx raises $8.5M (release) Cancer-vaccine maker ImmunoVaccine Tec... |
| - | MicroRNA-based cancer therapy firm scoops up $34.5 million, eyes 2013 IND filing | Company name: Mirna Therapeutics. Industry: biopharmaceuticals. Location: Austin, Texas. Solution/product: Mirna develops cancer therapies based on tumor suppressor microRNAs, which regain control over oncogenic pathways to kill cancer cell... |
Show more